Jiyeon Son
Team Leader GC Biopharma
Dr. Ting-Wan Lin is Director of Business Development and Project Management at GenomeFrontier Therapeutics, a clinical-stage biotechnology company pioneering next-generation virus-free gene and cell therapies. She leads global business development and strategic partnership initiatives supporting the advancement of GenomeFrontier’s Quantum Engine™ platform and innovative CAR-T programs.
Seminars
Thursday 12th November 2026
Development of Lipid Nanoparticles for Precision mRNA Delivery: Advancing From Protein Replacement to In Vivo Genome Editing & CAR-T Cell Programming
9:30 am
- Rational Design of Ionizable Lipid Libraries: Application of Structure-Activity Relationship (SAR) modeling and AI guided molecular design to develop a proprietary lipid library with an optimized therapeutic index and enhanced clinical tolerability
- Optimization for Hepatic Genome Editing: Identification and selection of LNP formulations tailored for high efficiency hepatic delivery, facilitating the technical transition from transient protein replacement to permanent genetic intervention with minimal off-target toxicity
- Strategic Engineering for in vivo CAR-T Programming: Development of LNP formulations specifically optimized to maximize T-cell delivery efficiency, enabling precise in vivo CAR-T cell programming through systemic mRNA delivery
